Article History
Received: 3 May 2024
Accepted: 8 May 2024
First Online: 27 May 2024
Disclosures
: Ken Kato reports funding from Merck Sharp & Dohme Corp. (MSD), Ono Pharmaceuticals, Bristol Myers Squibb (BMS), Beigene, Shionogi, Merck Biopharma, Oncolys BioPharma, Daiichi Sankyo, Novartis, Taiho Pharmaceutical, Janssen, AstraZeneca, and Chugai, paid to his institution. Yuto Kubo and Hiroyuki Daiko have no disclosures to declare in relation to this work.